Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Douglas Williams, Barry Greene, Stanley Crooke, Yitzhak Peterburg

Premium

Regulus Therapeutics has appointed Douglas Williams to its board of directors.

Williams is currently executive vice president of research and development at Biogen Idec, a Regulus collaborator that recently purchased a $5 million convertible note from the firm.

Concurrent with Williams' appointment, Regulus said that directors Barry Greene and Stanley Crooke have stepped down. Greene is president and COO of Alnylam Pharmaceuticals and Crooke is chairman and CEO of Isis Pharmaceuticals, which created Regulus as a joint venture.


Rosetta Genomics has appointed Yitzhak Peterburg to its board of directors.

Peterburg has served on the boards of Teva Pharmaceuticals, and was president and CEO of Cellcom.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.